The Claim
In adults with newly diagnosed Graves' disease, adding a daily supplement of 500 mg L-carnitine and 83 mcg selenium to methimazole therapy increases the rate of spontaneous remission to 63.3% compared to 13.3% with methimazole alone.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Adults with newly diagnosed Graves' disease who take L-carnitine and selenium along with methimazole experience spontaneous remission at a rate of 63.3%, while those taking methimazole alone experience remission at a rate of 13.3%.
See the scientific wording
Adding a daily supplement of 500 mg L-carnitine and 83 mcg selenium to methimazole therapy in adults with newly diagnosed Graves' disease significantly increases the rate of spontaneous remission to 63.3% compared to 13.3% with methimazole alone, suggesting a synergistic effect that may shorten disease duration and reduce reliance on long-term antithyroid medication.
L-carnitine blocks thyroid hormones from entering cells, so they cannot overstimulate the body’s metabolism, while selenium reduces harmful oxidative stress and calms the immune system, causing the antibodies that trigger the disease to disappear faster. Together, they stop the immune system from attacking the thyroid, allowing it to return to normal function.
What the research says
1 studyWhen people with Graves' disease took L-carnitine and selenium pills along with their regular medicine, they were much more likely to get better without needing surgery or radiation. The study shows this combo helped their bodies recover faster.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.